CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS

Interventions for the Diagnosis, Treatment, or Management of Conditions of the Small Bowel: Guidelines
SUMMARY OF ABSTRACTS

Interventions for the Diagnosis, Treatment, or Management of Conditions of the Small Bowel

Authors: Michelle Clark, Danielle Rabb


Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
**Research Questions**

1. What are the evidence-based guidelines regarding interventions to diagnose conditions of the small bowel?
2. What are the evidence-based guidelines regarding interventions to treat or manage conditions of the small bowel?

**Key Findings**

Six evidence-based guidelines were identified regarding interventions to diagnose, treat, or manage conditions of the small bowel.

**Methods**

A limited literature search was conducted on key resources including PubMed, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to health technology assessments, systematic reviews, meta-analyses, and guidelines. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2012 and May 17, 2017. Internet links were provided, where available.

**Selection Criteria**

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

<table>
<thead>
<tr>
<th>Table 1: Selection Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population</strong></td>
</tr>
<tr>
<td><strong>Intervention</strong></td>
</tr>
<tr>
<td><strong>Comparator</strong></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
</tr>
<tr>
<td><strong>Study Designs</strong></td>
</tr>
</tbody>
</table>
Results

Six evidence-based guidelines were identified regarding interventions to diagnose, treat, or manage conditions of the small bowel.

Additional references of potential interest are provided in the appendix.

Overall Summary of Findings

Recommendations for capsule endoscopy (CE) for visualisation of the small bowel are reported in three guidelines.\(^1\)\(^4\)\(^6\) When described, the strength of the evidence to support the recommendation has been provided. In these guidelines, CE is recommended for:

- Investigation of the small bowel for patients with current or suspected Crohn’s disease when ileocolonoscopy and other imaging studies were negative,\(^1\)
- Assessment, but not treatment, of patients with celiac disease with unexplained symptoms and adequate treatment,\(^1\)
- Assessment of patients with suspected celiac disease who are unwilling or unable to have investigation by conventional endoscopy (strong recommendation, low quality evidence),\(^4\)
- Only in selected patients with unexplained, mild, chronic iron-deficiency anemia,\(^1\)
- Surveillance of patients with small bowel cancers who need small bowel studies,\(^1\)
- “…first-line investigation in patients with obscure gastrointestinal bleeding (strong recommendation, moderate quality evidence),”\(^4\)
- Overt obscure gastrointestinal bleeding as soon as possible (within 14 days) after the bleeding episode (strong recommendation, moderate quality evidence),\(^4\)
- General diagnosis of patients with small bowel disease after other diagnostic methods have been attempted.\(^6\)

Abstracts outlining aims and methodology were identified for three additional guidelines\(^2\)\(^3\)\(^5\) regarding the use of CE for investigation of the small bowel. However, because the recommendations were not summarized within the abstracts, the recommendations have not been summarized in this report.

The European Society of Gastrointestinal Endoscopy\(^4\) recommends “…device-assisted enteroscopy to confirm and possibly treat lesions identified by capsule endoscopy (strong recommendation, high quality evidence).”

References Summarized

Guidelines and Recommendations


Appendix — Further Information

Previous CADTH Reports

Economic Evaluations
PubMed: PM26355732

Clinical Practice Guidelines – Methodology Not Stated
PubMed: PM26303132

PubMed: PM22987220

Review Articles
PubMed: PM27070909

PubMed: PM26667868

PubMed: PM24567648

PubMed: PM23840112
Additional References


